On June 21, Fuyuan Pharmaceutical (601089.SH) opened the subscription, the subscription price was 14.62 yuan per share, and the subscription limit was 36,000 shares, which belonged to the main board of the Shanghai Stock Exchange.CITIC Construction Investment Securitiesas its sole sponsor.
Fuyuan Pharmaceutical is mainly engaged in the research and development, production and sales of pharmaceutical preparations and medical devices. With the mission of “focusing on the field of medicine and creating a healthy life together”, the company is committed to creating a core competitive advantage of R&D, production and sales. The company has been selected as a G20 enterprise in the leap-forward development project of Beijing pharmaceutical industry, and has been listed in the top 100 list of China’s chemical research and development strengths and the top 100 list of Beijing private enterprises in scientific and technological innovation.
The company’s product categories are rich, and its pharmaceutical preparations currently mainly cover cardiovascular system, chronic kidney disease, dermatology, digestive system, diabetes, mental nervous system, gynecology and other product segments. It has losartan potassium. Hydrochlorothiazide Tablets, Olmesartan Medoxomil Tablets, Telmisartan Tablets, Trimetazidine Hydrochloride Tablets, Atorvastatin Calcium Tablets, Compound Alpha-Keto Acid Tablets, Hacinide Solution, Pinaverium Bromide Tablets, Kaisailu , repaglinide tablets, gliclazide sustained-release tablets, acarbose tablets, paroxetine hydrochloride tablets, venlafaxine hydrochloride sustained-release capsules, progesterone soft capsules and other major products; The equipment business mainly focuses on humidification and oxygen inhalation devices, and the main products include disposable oxygen inhalation tubes.
Up to now, in the field of pharmaceutical preparations, the company has 9 first domestic imitation products, 23 varieties have passed the consistency evaluation or deemed to have passed the consistency evaluation, and have made layouts in new fields such as chemical innovative drugs; in the field of medical devices, the company focuses on clinical care Product-based, household medical products supplemented by micro-innovation, and has independent intellectual property rights. The company’s technical reserves are relatively sufficient. As of the end of the reporting period, the company has 282 authorized patents, including 87 invention patents. 4 research projects.
In terms of finance, in 2019, 2020 and 2021, Fuyuan Pharmaceutical’s operating income was about 2.4247 billion yuan, 2.5354 billion yuan and 2.8377 billion yuan respectively; in the same period, the company’s net profit was 220.4 million yuan, 264.5 million yuan and 319.6 million yuan respectively. Yuan Renminbi.
Massive information, accurate interpretation, all in Sina Finance APP